Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03421652 · ClinicalTrials.gov registry record · Phase 2
Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo
A Phase 2 study of Stage IV Bladder Urothelial Carcinoma AJCC v7 and Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT03421652 is a Phase 2 study of Stage IV Bladder Urothelial Carcinoma AJCC v7 and Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 20 participants, below the 546-participant average among 5 other Stage IV Bladder Urothelial Carcinoma AJCC v7 trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03421652, a Phase 2 study of Stage IV Bladder Urothelial Carcinoma AJCC v7 and Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial studies how well nivolumab works with radiation therapy in treating patients with urothelial bladder cancer that has spread from its original site of growth to nearby tissues or lymph nodes and are ineligible for chemotherapy. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving nivolumab and radiation therapy may work better in treating patients with urothelial bladder cancer.
Conditions Studied
Interventions
- DRUG Nivolumab
- RADIATION Radiation
Study Locations (2)
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
New York
- Roswell Park Cancer Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-04-24 |
| Est. Completion | 2023-03-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03421652
The ClinicalTrials.gov registry entry for NCT03421652 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 5 other Stage IV Bladder Urothelial Carcinoma AJCC v7 trials with a reported enrollment target (96% lower). The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Stage IV Bladder Urothelial Carcinoma AJCC v7 appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT03421652 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Michigan, New York.
Frequently Asked Questions
What is clinical trial NCT03421652 about?
NCT03421652 is a clinical study titled "Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo". This phase II trial studies how well nivolumab works with radiation therapy in treating patients with urothelial bladder cancer that has spread from its original site of growth to nearby tissues or lymph nodes and are ineligible for chemotherapy. Monoclonal antibodies, such as nivolumab, may interfe...
What is the current status of trial NCT03421652?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2018-04-24. Estimated completion is 2023-03-23.
What conditions does trial NCT03421652 study?
This clinical trial studies the following conditions: Stage IV Bladder Urothelial Carcinoma AJCC v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7.
What interventions are being tested in trial NCT03421652?
The interventions under investigation include: Nivolumab (DRUG), Radiation (RADIATION).
Who is sponsoring clinical trial NCT03421652?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03421652 being conducted?
This trial has 2 study locations across Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Bladder Urothelial Carcinoma AJCC v7
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
RECRUITING · Phase 2
-
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
ACTIVE NOT RECRUITING · Phase 2
-
Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer
COMPLETED · Phase 2
-
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
RECRUITING
-
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Stage IV Bladder Urothelial Carcinoma AJCC v7
All registered trials for this condition
Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
All registered trials for this condition
Michigan
All trials with a study site in Michigan
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.